目前，经国家结核病规划所查明的病例在估计的耐多药结核病例中所占比例不足5%。
Currently, less than 5% of the estimated MDR-TB cases are being detected by national TB programmes.
对那些经济增长很快并且面临耐多药结核病沉重负担的国家而言，现在到了加强承诺并为自身的耐多药结核病项目提供资助的时候了。
It is time for countries with rapidly growing economies and a heavy burden of MDR-TB to step up their commitment and financing for their own MDR-TB programmes.
三个三期药物实验预计在2012年和2013年之间会得出结论，预计在2012年得到两项新的耐多药结核病药物二期实验的结果。
Results from three Phase III drug trials are expected between 2012 and 2013, while results from two Phase II trials of new MDR-TB drugs are expected in 2012.
2010年耐多药结核病病人得到治疗的人数上升到了4.6万人，而这仅仅占到需要得到治疗的耐多药结核病病人估计数字的16%。
While the number of MDR-TB patients treated increased to 46 000 in 2010 - this is just 16% of the estimated number of MDR-TB patients that needed treatment.
在马尼拉一家耐多药结核病诊所，我看到48岁的AntiaSilverio在刚刚结束5个月的耐多药结核病治疗后为医生、护士和病人跑腿打下手。
At one MDR-TB clinic in Manila, I watched Antia Silverio, a 48-year-old who had just finished her MDR-TB treatment five months before, run errands for doctors, nurses and patients.
控制耐多药结核病的努力特别容易受到这类压力的影响，因为需要高水平的人力资源来有效诊断和治疗患者。
Efforts to control MDR-TB are particularly vulnerable to such pressures because of the high level of human resources needed to diagnose and treat patients effectively.
2009年，耐多药结核病的情形大致相同，这就提醒我们：既存在着威胁，也存在即使在最艰难的环境中也可控制这种威胁的模式。
In 2009, the situation is much the same for MDR-TB, an awakening both to the threat and to models that can control it even in the most challenging Settings.
这就是耐多药结核病的出现和传播所带来的前景。
This is the perspective created by the emergence and spread of drug-resistant tuberculosis.
世卫组织今年早些时候发布的一个报告表明，耐多药结核病发病率已达到记录新高。
Earlier this year, WHO issued a report showing that multi-drug resistant TB has reached the highest levels ever recorded.
问：你们的国家结核病实验室现在被认为是目前非洲最先进的之一，包括使用在48小时内检测是否是耐多药结核病的一项新技术。
Q: Your national TB laboratory is now regarded as one of the most advanced in Africa – including the use of a new technology that within 48 hours can detect whether a person has MDR-TB.
对普通结核病的不规范治疗致使耐多药菌株滋生繁殖。
Substandard treatment of normal TB drives the development of multi-drug resistant strains.
为了支持北京会议的目标，帮助各国扩展耐多药结核病控制的计划工具正在开发中。
In support of the Beijing meeting's aims, planning tools are being developed to help countries scale up their MDR-TB control efforts.
用于疗耐多药结核病漫长治疗的药品费用比治疗常见结核病菌株的药品可能贵100倍以上。
The drugs for the lengthy treatment of MDR-TB can cost more than 100 times that of the drugs to treat common tuberculosis strains.
如果按照控制结核战略的建议在整个卫生系统中紧急采取结核病控制措施，就可制止耐多药结核病和广泛耐药结核病的全球威胁。
The global threat of MDR-TB and XDR-TB (M/XDR-TB) can be halted if TB control measures are urgently put in place across the whole health system as recommended under the Stop TB Strategy.
问：哈萨克斯坦与耐多药结核病作斗争的核心内容是什么？
Q: What's the most important part of Kazakhstan's fight against drug-resistant TB?
到2005年，绿灯委员会行动已积累了足够的证据，为制定在贫困环境中治疗耐多药结核病的新世卫组织政策铺平了道路。
By 2005, the Green Light Committee Initiative had accumulated enough evidence to pave the way for a new WHO policy on treating MDR-TB in poor Settings.
世卫组织现在呼吁，在具有明确界定的条件下并且作为结核病和耐多药结核病治疗控制国家计划的部分内容推出全自动核酸扩增试验。
WHO is now calling for the fully automated NAAT to be rolled out under clearly defined conditions and as part of national plans for TB and MDR-TB care and control.
全球范围内，接受治疗的病人当中，有60%报告治愈，但耐多药结核病病人中，只有大约7%得以确诊。
Worldwide, of those patients receiving treatment, 60% were reported as cured. However, only an estimated 7% of all MDR-TB patients are diagnosed.
感染艾滋病毒者罹患耐多药结核病的风险较大，其死亡率大幅上升，存活时间大大减少。
People living with HIV have a higher risk of MDR-TB, with a greatly increased mortality and a greatly reduced survival time.
问：你对与耐多药结核病作斗争的前途有什么看法？
这向我们发出了真正的预警信号：如何不能切实有力地遏制耐多药结核病，它会随时取代目前造成全球95%的结核病例的主要药物敏感菌株。
This is the true warning signal: if MDR-TB is not vigorously addressed, it stands to replace the mainly drug-susceptible strains currently responsible for 95% of the world's TB cases.
问：你什么时候开始介入耐多药结核病问题的？
你可以通过相当简单的卫生保健基础设施处理药物敏感结核病，而涉及到耐多药结核病时，你将需要更加复杂的设施。
You can deal with drug-susceptible TB with fairly simple health-care infrastructure, when it comes to MDR-TB what you need is more sophisticated.
耐多药结核病的蔓延引起了人们的特别关注，尤其是在东欧、中亚部分和中国。
The spread of multi-drug resistant TB is a cause of particular concern, especially in Eastern Europe, parts of Central Asia, and China.
回到前抗生素时代的威胁是真实的，而耐多药和广泛耐药结核病的增多则是最生动的实例。
The threat of returning to a pre-antibiotic era is genuine and probably most vividly illustrated by the rise of multidrug-resistant and extensively drug-resistant tuberculosis.
自2009年以来，受到耐药结核病影响最重的23个国家已经将用于耐多药结核病的预算几近翻番。
Since 2009, the 23 countries most heavily affected by TB drug resistance have nearly doubled their budgets for MDR-TB.
进一步的检测显示，那些治疗失败的病人患的是耐多药结核病，官员意识到了耐多药结核病的流行。
Further tests revealed those who failed treatment had MDR-TB; officials realized they had an epidemic of these cases.
进一步的检测显示，那些治疗失败的病人患的是耐多药结核病，官员意识到了耐多药结核病的流行。
Further tests revealed those who failed treatment had MDR-TB; officials realized they had an epidemic of these cases.
应用推荐